tech Eli Lilly and Profluent Ink $2.25 Billion Deal for AI-Designed Genetic Medicines
Eli Lilly partners with AI firm Profluent in a major collaboration aiming to develop novel genetic medicines using advanced artificial intelligence for complex diseases.
